Literature DB >> 33407861

Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade.

Aradhana M Venkatesan1, Eniola Mudairu-Dawodu2, Cihan Duran3, R Jason Stafford4, Yuanqing Yan5, Wei Wei5, Vikas Kundra1,6.   

Abstract

BACKGROUND: The utility of multiparametric MRI (mpMRI) in detecting suspected local recurrence post radical prostatectomy (RP) may be associated with PSA and Gleason grade. The purpose of the study was to evaluate the likelihood of detecting locally recurrent prostate cancer utilizing mpMRI in patients with suspected recurrence following radical prostatectomy (RP) parsed by PSA and Gleason grade.
METHODS: One hundred ninety five patients with suspected local recurrence were imaged on a 1.5 T MRI with torso array and endorectal coil in this retrospective study. mpMRI interpretations were stratified by PSA and lower (Gleason < 7) vs. higher grade tumors (Gleason 8-10). Recursive partitioning was used to determine whether mpMRI interpretations could be classified as positive or negative.
RESULTS: The majority of mpMRI interpretations in patients with lower Gleason grade tumors and PSA < 0.5 ng/mL were negative (68/78, 87.2%, p = 0.004). The majority of mpMRI interpretations in patients with higher Gleason grade tumors and PSA > 1.5 ng/mL were positive (8/9, 88.9%, p = 0.003). Findings were corroborated by recursive partitioning, which identified a PSA = 0.5 ng/ml in patients with lower grade tumors and a PSA = 1.5 ng/mL in patients with higher grade tumors as differentiating negative and positive mpMRIs.
CONCLUSION: In the setting of suspected recurrence after RP, mpMRI results are associated with PSA and Gleason grade, both of which can help guide when mpMRI may find utility. mpMRI is likely to be low diagnostic yield and negative for recurrence (87%) in the setting of lower Gleason grade tumors and PSA < 0.5 ng/mL. mpMRI is likely to be of low diagnostic value and positive for recurrence (89%) in the setting of PSA > 1.5 ng/mL and higher grade tumors; in this case, mpMRI findings may be more useful for directing biopsy and local therapy. Between these extremes, PSA > 0.5 ng/mL and lower grade tumors or PSA < 1.5 ng/mL and higher grade tumors, mpMRI results are less predictable, suggesting greater diagnostic value for detecting recurrence post prostatectomy.

Entities:  

Keywords:  Multiparametric MRI; Prostate cancer; Radical prostatectomy; Recurrence

Year:  2021        PMID: 33407861     DOI: 10.1186/s40644-020-00373-4

Source DB:  PubMed          Journal:  Cancer Imaging        ISSN: 1470-7330            Impact factor:   3.909


  32 in total

1.  Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?

Authors:  Peeyush Bhargava; Gregory Ravizzini; Brian F Chapin; Vikas Kundra
Journal:  AJR Am J Roentgenol       Date:  2020-03-04       Impact factor: 3.959

2.  A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.

Authors:  Pieter J L De Visschere; Chloë Standaert; Jurgen J Fütterer; Geert M Villeirs; Valeria Panebianco; Jochen Walz; Tobias Maurer; Boris A Hadaschik; Frédéric E Lecouvet; Gianluca Giannarini; Stefano Fanti
Journal:  Eur Urol Oncol       Date:  2018-10-24

Review 3.  Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Authors:  Sonia Gaur; Baris Turkbey
Journal:  Radiol Clin North Am       Date:  2017-11-27       Impact factor: 2.303

Review 4.  Defining prostate cancer risk after radical prostatectomy.

Authors:  S Adamis; I M Varkarakis
Journal:  Eur J Surg Oncol       Date:  2014-02-20       Impact factor: 4.424

5.  Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

Authors:  C L Amling; E J Bergstralh; M L Blute; J M Slezak; H Zincke
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

6.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.

Authors:  Andrew J Stephenson; Michael W Kattan; James A Eastham; Zohar A Dotan; Fernando J Bianco; Hans Lilja; Peter T Scardino
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

7.  Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.

Authors:  Valeria Panebianco; Flavio Barchetti; Alessandro Sciarra; Daniela Musio; Valerio Forte; Vincenzo Gentile; Vincenzo Tombolini; Carlo Catalano
Journal:  Eur Radiol       Date:  2013-02-02       Impact factor: 5.315

8.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Authors:  Misop Han; Alan W Partin; Marianna Zahurak; Steven Piantadosi; Johnathan I Epstein; Patrick C Walsh
Journal:  J Urol       Date:  2003-02       Impact factor: 7.450

Review 9.  Management of patients with an increasing prostate-specific antigen after radical prostatectomy.

Authors:  Masood A Khan; Alan W Partin
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

10.  Whole-body diffusion-weighted imaging with background body signal suppression in the detection of osseous and extra-osseous metastases.

Authors:  Ahmed Abdel Razek; Ahmed Tawfik; Mariam Abdel Rahman; Saleh Teima
Journal:  Pol J Radiol       Date:  2019-11-12
View more
  3 in total

Review 1.  Diffusion-Weighted MRI in the Genitourinary System.

Authors:  Thomas De Perrot; Christine Sadjo Zoua; Carl G Glessgen; Diomidis Botsikas; Lena Berchtold; Rares Salomir; Sophie De Seigneux; Harriet C Thoeny; Jean-Paul Vallée
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

2.  Application Value of Radiomic Nomogram in the Differential Diagnosis of Prostate Cancer and Hyperplasia.

Authors:  Shaogao Gui; Min Lan; Chaoxiong Wang; Si Nie; Bing Fan
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

3.  Pathological predictors of 18 F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.

Authors:  Elisa Perry; Arpit Talwar; Kim Taubman; Michael Ng; Lih-Ming Wong; Tom R Sutherland
Journal:  BJU Int       Date:  2022-06       Impact factor: 5.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.